Loading
A phase 3 trial testing QL1706 in colorectal cancer, now recruiting.
A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer is a phase 3 interventional study registered as NCT06686576, led by Qilu Pharmaceutical, and recruiting on the registry. Official title: A Phase Ib/III, Open-Label, Randomised Study of Neoadjuvant QL1706 Versus Standard of Care in Participants With Untreated of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer. Planned enrolment is 363 participants (estimated). The study started in 2024-12-12 and primary completion is expected in 2030-12. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares QL1706, Qilu Pharmaceutical.
Shares QL1706, Qilu Pharmaceutical.
Shares QL1706, Mismatch-repair deficient (MSI-high) colorectal cancer.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer.
Shares QL1706, Qilu Pharmaceutical.
Shares QL1706, Qilu Pharmaceutical.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/